Efficacy analysis of multidisciplinary treatment for Wilms tumor in a single center

Abstract

Objective: To analyze the e cacy of multidisciplinary treatment (MDT) for Wilm's tumor (WT) in Kunming Children's Hospital, and investigate the risk factors affecting the prognosis of WT.Method: The clinic-pathological data were collected and analyzed in patients with unilateral WT treated in Kunming Children's Hospital from January 2017 to July 2021. Research objects were selected according to inclusion criteria and exclusion criteria. The risk factors and independent risk factors that affect the prognosis of patients with WT were determined by Kaplan-Meier survival analysis and Cox proportional hazards model, respectively.Outcome: A total of 68 children were included in this study, and the 5-year overall survival (OS) rate was 92.65%. Kaplan-Meier survival analysis results showed that ethnicity (P=0.020), the tumor volume of resection (P=0.001), histological type (P<0.001), and postoperative recurrence (P<0.001) were the factors affecting the prognosis of children with WT. The results of the Cox proportional hazards model showed that only the histological type (P=0.028) was the independent risk factor for the prognosis of WT. Conclusion:The e cacy of MDT for WT was satisfying. The histological type has important predictive value for the prognosis of WT, and the patient with unfavorable histology has a poor prognosis.

Screening of potential hub genes involved in Kidney Wilms tumor via bioinformatics analysis and experimental validation

“…Wilms tumor (WT) is the most common pediatric renal malignancy [9]. The outcomes for patients with Wilms' tumors (WTs) have signi cantly improved over the last decades, because of the advances in multimodel therapy including surgery, chemotherapy, and radiation therapy, and allowed most patients with > 90% overall survival for those with localized, and 80% for those with metastatic nonanaplastic WT [10][11][12]. Surgical removal of the diseased kidney has limitations because current treatments are not entirely appropriate for some populations, especially infants and children, and patients with bilateral tumors [13,14].…”